Materia, a medical cannabis and wellness company focused on the European market, today announced that its wholly-owned subsidiary Materia Deutschland GmbH (“Materia Deutschland“) has entered into a partnership with German diagnostics company Saxonia Diagnostics GmbH (“Saxonia Diagnostics”) for the exclusive distribution of its branded cannabis testing products across Germany.

These products, which will be sold under the CannaFix-ID^® brand, offer a highly efficient alternative to cannabis dispensing pharmacies, which are required under German regulations to test medical cannabis due to its status as a magisterial preparation. The innovative technology is expected to ease the cumbersome process by which cannabis products are currently tested in Germany.

“The German DAB monograph requires pharmacies to test products with the time-consuming, often expensive thin layer chromatography or an otherwise comparable method. This is often a barrier for broad adoption of medical cannabis by pharmacies. The CannaFix-ID^® portfolio represents an exciting alternative that is qualified as a comparable method. This makes testing for pharmacies much easier and more economical,” said Sebastian Blöte, Managing Director of Materia Deutschland. “We are happy to be working with Saxonia, whose team has deep pharmaceutical expertise, especially in the area of medical cannabis. Their vision of offering convenient and efficient solutions to pharmacies is perfectly aligned with our own.”

The first product to be made available under the partnership will be a validated THC test kit that can be used for flower, extracts and dronabinol. The second will offer both THC & CBD testing of flower and extracts. Both tests have been successfully validated for a bundle of different medical cannabis products.

“The comprehensive validation with an easy-to-use approach is an essential prerequisite to overcome hurdles for the broader dispensing of medical cannabis”, said Michael Pfeffer, Managing Director of Saxonia Diagnostics.

The products have been developed, validated and tested in Germany. The official market launch into German pharmacies is planned for May 2021.